Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.

Last updated: March 11, 2022
Sponsor: Fernando López Zárraga
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04197544
FAVIS
  • Ages > 18
  • All Genders

Study Summary

In last few years, there is a new technology that permits the endovascular fistula creation with a minimum vascular trauma and the first results show encouraging results with high technical success rate, low resurgent and failure rates and good usability for hemodialysis.

The implementation of the endoFAVI realization in dialysis patients is an emergent procedure that in our hospital can contribute important benefits to the patients, savings to the health system, as well research and innovation in the implicate services.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult (older than 18).
  • Currently be receiving chronic dialysis, or be waiting to start the chronic dialysisin the next six months.
  • Have veins with diameter >= 2.0mm to the creation of the fistula, established byDuplex ultrasound or venogram.
  • Have arteries with diameter >= 2.0mm to the creation of the fistula, established byDuplex ultrasound or venogram.
  • Cubital and radial arterial flow for the hand, confirmed with Duplex Ultrasound and/orAllen test.
  • Dismissed the realization of cephalic-radius FAVI for surgical technical problems.
  • Informed Consent to participate in the study.

Exclusion

Exclusion Criteria:

  • Known central venous stenosis or narrowing of the central vein > 50% according toimages on the same side as the creation of the planned FAV.
  • Absence of perforator that feed the target cannulation, by venogram.
  • Occlusion or stenosis > 50% of the cephalic basilica vein of the target cannulation.
  • Cannulation target vein of less than 2.0 mm of diameter.
  • Significantly compromised flow (>= 50% of stenosis) in the treatment arm as determinedby the doctor and the images.
  • Ejection fraction documented <= 35% in the last 6 months.
  • Pregnant women.
  • Heart failure Class III or IV of the New York Heart Association (NYHA).
  • Hypercouagulability status demonstrated ( Antiphospholipid Syndrome, Leiden factor V,Protein deficit S, ...).
  • Known hemorrhagic diathesis.
  • Documented history of drug abuse including intravenous drugs within six months of FAVcreation.
  • Concomitant major surgical procedure "planned" within three months of recruitment ormajor previous surgery within 30 days of recruitment.
  • Known iodine contrast allergy that cannot be properly premedicated.
  • Known adverse effects for sedation and/or anesthesia that cannot be properlypremedicated.
  • Evidence of active infections on the day of the index procedure.
  • Life expectancy < 1 year.
  • The patient is not willing to provide an written informed consent, is notgeographically stable and/or is not willing to cmply with the required follow-up.
  • Patient with an objective cannulation vein of more than 6 mm of deep that wouldrequire a transposition procedure, defined as the elevation of an objectivecannulation vein nad the creation of a new fistula AV.
  • The patient is nit willing to undergo of second stage, defined as a conversion tosurgical FAVI, central catheter arrangement, thrombectomy/rescue fibrinolysis, stenoicarea angioplasty, ...

Study Design

Total Participants: 14
Study Start date:
July 28, 2021
Estimated Completion Date:
January 31, 2023

Connect with a study center

  • Araba University Hospital (Santiago

    Vitoria-Gasteiz,
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.